Haemonetics

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Haemonetics reports robust Q1 earnings, eyes U.S. growth amid challenges

Haemonetics delivered strong financial performance in Q1 fiscal 2023, driven by robust revenue growth in both the Plasma and Hospital segments. The company's focus on the U.S. market and plans for accelerating growth indicate a positive outlook. However, challenges related to potential cuts in donor payments and varying market conditions outside the U.S. require careful navigation.

Haemonetics Corporation reports robust Q1 fiscal 2024 performance and eyes international expansion

Haemonetics Corporation delivered impressive Q1 fiscal 2024 results, driven by strong revenue growth and improved operating income. The company faces challenges in managing inventory replenishment and potential competition in the autoimmune space. However, opportunities lie in leveraging its robust product portfolio and expanding into international markets.

Haemonetics reports strong Q3 performance, eyes European expansion for growth

Haemonetics delivered robust financial results in Q3, driven by strong revenue growth and strategic initiatives. While facing challenges related to staffing and donor issues, the company is well-positioned to leverage opportunities in expanding markets and technological advancements to drive future growth.

Haemonetics posts robust earnings, eyes global expansion for growth

Haemonetics delivered strong financial results in Q4 2023 and fiscal '23, driven by robust revenue growth and improved earnings per share.
The company's focus on key segments like Plasma, Hospital, Hemostasis, and Vascular Closure positions it well for future growth and market expansion.
While facing challenges such as cost pressures and competitive landscapes, Haemonetics remains optimistic about its ability to drive profitability and market share.
Strategic initiatives, including a modest ramp in market resources and international expansion, present opportunities for Haemonetics to capitalize on market demand and enhance shareholder value.

Haemonetics excels in Q1 '24, eyes growth amid challenges

Haemonetics delivered robust financial performance in Q1 '24, with significant revenue growth and margin expansion.
While facing challenges like product recalls, the company remains focused on value creation and growth acceleration strategies.
Opportunities for growth exist through market scaling, product innovations, and leveraging trial implications for demand growth.

Haemonetics posts robust Q2 earnings, eyes U.S. and international growth

Haemonetics reported strong Q2 results with increased earnings and revenue growth. The company's strategic acquisitions and focus on innovation position it well for future expansion. Challenges in the Blood Center segment require attention, but overall, Haemonetics is poised for continued growth.

Haemonetics posts robust Q3 earnings, eyes growth through innovation

Haemonetics delivered strong financial performance in Q3 2024, driven by revenue growth and operational efficiency improvements.
The company's focus on innovation, technology enhancements, and strategic acquisitions positions it well for future growth and market leadership.
While facing challenges in certain revenue segments, Haemonetics remains poised to capitalize on opportunities for expansion and margin improvement.

Haemonetics posts robust Q4 results, eyes growth through acquisitions

Haemonetics' Q4 2024 performance reflects strong revenue growth and profitability, driven by successful product launches and acquisitions.
While the company faces challenges in margin targets and integration post-acquisitions, strategic focus on innovation and market expansion presents growth opportunities.
Emphasis on non-GAAP measures and regulatory clearances underscores Haemonetics' commitment to transparency and product quality.
Fiscal year 2025 guidance signals a positive outlook for revenue growth and operational efficiency, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Lightspeed Commerce Inc

MINISO Group Holding

MNSO, LSPD and HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 28, 2023.

Best Momentum Stocks to Buy for May 28th

Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook Haemonetics (HAE)

The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Haemonetics (HAE) Could Rally 26.58%: Here's is How to Trade

Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Haemonetics (HAE) Upgraded to Strong Buy: What Does It Mean for the Stock?

BOSTON , May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $525,000,000 aggregate principal amount of notes.

Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes

Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).

Here's Why You Should Buy Haemonetics (HAE) Stock Now

BOSTON, May 21, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000 aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").  Haemonetics also expects to grant the initial purchasers of the notes an option to purchase up to an additional $75,000,000 aggregate principal amount of the notes.

Haemonetics Announces Proposed Convertible Senior Notes Offering

Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid

Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.

Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?

Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Haemonetics Corporation (HAE) Hit a 52 Week High, Can the Run Continue?

Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.

Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand

Haemonetics Corporation (NYSE:HAE ) Q4 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Olga Guyette - Senior Director of Investor Relations and Treasury Christopher Simon - President and Chief Executive Officer James D'Arecca - Executive Vice President and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuno Group Larry Solow - CJS Securities Joanne Wuensch - Citi Andrew Cooper - Raymond James Mike Matson - Needham & Company Michael Petusky - Barrington Research David Turkaly - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Q4 2024 Haemonetics Corporation Earnings Conference Call.

Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript

The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say

Haemonetics (HAE) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.77 per share a year ago.

Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates

Financial release accessible online BOSTON , May 9, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Royal Philips

Investors interested in stocks from the Medical - Products sector have probably already heard of Royal Philips (PHG) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?

PHG vs. HAE: Which Stock Is the Better Value Option?

Evaluate the expected performance of Haemonetics (HAE) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Exploring Analyst Estimates for Haemonetics (HAE) Q4 Earnings, Beyond Revenue and EPS

Haemonetics (HAE) Banks on Plasma Arm Growth Amid Rising Costs

Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).

Why You Should Add Haemonetics (HAE) to Your Portfolio Now

BOSTON , April 10, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday, May 9, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 9, 2024.

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024

Abbott Labs

Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Abbott (ABT). But which of these two stocks is more attractive to value investors?

HAE vs. ABT: Which Stock Is the Better Value Option?

Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.

Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval

BOSTON , April 4, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries/procedures and liver transplantation in both laboratory and point-of-care settings.

Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge

BOSTON , April 1, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has completed its previously announced acquisition of privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device. EnsoETM is the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency (RF) cardiac ablation procedures.

Haemonetics Corporation Completes Acquisition of Attune Medical

After reaching an important support level, Haemonetics (HAE) could be a good stock pick from a technical perspective. HAE surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.

News for Haemonetics Stock (HAE)